Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

Cambridge: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a ...

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.

Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...